Form 4: Allogene Therapeutics CEO Sells Shares to Cover Tax Obligations

Allogene Therapeutics CEO David Chang sold shares to cover tax withholding obligations related to vesting restricted stock units, as mandated by the company's equity incentive plan.

Summary

• On March 14, 2024, David Chang, the President and CEO of Allogene Therapeutics, sold 53,393 shares of common stock at a weighted average price of $4.33 per share to cover tax withholding obligations.
• The sale was mandated by Allogene's equity incentive plan, requiring tax obligations to be funded through a 'sell to cover' transaction.
• Following the transaction, Chang directly owns 4,465,278 shares and indirectly owns 1,201,108 shares through the Chang 2006 Family Trust, 856,044 shares through the JEC 2019 Trust, and 856,044 shares through the RTC 2019 Trust.
• Chang also acquired 5,468 shares on March 15, 2024, through an employee stock purchase program.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't necessarily reflect a change in the executive's outlook on the company.

Positives

• The acquisition of 5,468 shares through the employee stock purchase program demonstrates Chang's continued investment in the company.

Industry Context

Sales to cover taxes are a routine part of equity compensation plans, especially for executives at publicly traded companies. This transaction is not necessarily indicative of a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Companies like Gilead Sciences, Amgen, and Biogen also have similar equity compensation plans that result in periodic stock sales by executives for tax purposes.
• The size of the sale is relatively small compared to the total holdings of the CEO, suggesting it is primarily for tax obligations rather than a strategic divestment.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price due to the increased supply.
• The transaction is unlikely to have a significant impact on employees, customers, or suppliers.

Key Dates